Vivoryon Therapeutics NV
Vivoryon Therapeutics NV is a biotechnology company focused on the development of novel therapies for the treatment of autoimmune and inflammatory diseases, primarily through its proprietary platform for the development of small molecule drugs.
Business. Vivoryon Therapeutics NV (VVY.AS) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the Netherlands and is primarily listed on the Euronext Amsterdam exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Vivoryon Therapeutics NV (VVY.AS) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the Netherlands and is primarily listed on the Euronext Amsterdam exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Vivoryon Therapeutics has a market capitalization of EUR 37.31 million, with a current market price of EUR 1.26 per share. The company holds EUR 22.00 million in cash and equivalents, indicating a strong liquidity position relative to its market cap. The absence of diluted shares suggests no immediate dilution risk from stock options or convertible instruments.
Profitability metrics are not available due to the company's reported zero revenue, which is typical for early-stage biotechnology firms in pre-commercial development. The company's financial structure is entirely equity-funded, with no disclosed debt or interest expenses. This capital structure is consistent with industry norms for firms in the pre-revenue phase.
Geographically, Vivoryon is headquartered in the Netherlands and operates primarily in the European biotechnology sector. The company has not disclosed segment-specific revenue figures, and its operations are not yet diversified across multiple therapeutic areas or geographic regions. This lack of diversification increases exposure to regulatory and clinical trial risks.
The company's growth trajectory is speculative, as it has not yet generated revenue. Analysts have assigned a mean price target of EUR 5.83, with a median of EUR 5.00, suggesting a potential upside of over 360% from the current market price. However, these estimates are based on pre-commercial development and do not reflect any near-term revenue visibility.
Risk factors include the absence of commercial products, reliance on successful clinical trials, and the need for additional capital to fund ongoing research and development. The company has not disclosed any immediate liquidity or dilution risks, but its zero revenue and ongoing R&D expenditures suggest a high dependency on future financing.
Recent events include the publication of preclinical data and the initiation of Phase I clinical trials for its lead candidate. No material regulatory or legal events have been disclosed in the latest filings. The company has not issued any recent press releases or investor updates beyond standard clinical trial progress reports.
- Vivoryon is a pre-revenue biotechnology firm with a strong cash position but no commercial products.
- The company's valuation is speculative, with analyst price targets suggesting a potential 360% upside.
- No immediate liquidity or dilution risks are present, but the company will require additional capital to fund ongoing R&D.
- The company's operations are concentrated in a single therapeutic area and geographic region, increasing exposure to clinical and regulatory risks.
- Analyst sentiment is cautiously optimistic, with a mean recommendation of 1.33 (strong buy to buy).
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue €0.00; Operating income +57,5% YoY.
- ▍Revenue €0.00
- ▍Operating income +57,5% YoY
- ▍Net income +57,0% YoY
- ▍Free cash flow +57,3% YoY
Revenue €0.00, +100,0% YoY; Operating income +27,3% YoY.
- ▍Revenue €0.00, +100,0% YoY
- ▍Operating income +27,3% YoY
- ▍Net income +27,4% YoY
- ▍Free cash flow +28,8% YoY
Revenue -€3.6M; Operating income +1,0% YoY.
- ▍Revenue -€3.6M
- ▍Operating income +1,0% YoY
- ▍Net income −0,7% YoY
- ▍Free cash flow −2,4% YoY
- ▍Net margin 782.9%
Revenue €0.00, −100,0% YoY; Operating income −125,7% YoY.
- ▍Revenue €0.00, −100,0% YoY
- ▍Operating income −125,7% YoY
- ▍Net income −122,5% YoY
- ▍Free cash flow −123,7% YoY
Revenue €10.8M; Operating income -€12.9M.
- ▍Revenue €10.8M
- ▍Operating income -€12.9M
- ▍Net margin -117.6%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,43 |
| Revenue | —no estimate | —no estimate | 0 EUR |
| Operating income | —no estimate | —no estimate | -11,6M EUR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Market Capmarket_price * shares_outstanding_diluted
- Enterprise Valuemarket_cap - net_cash
- Vivoryon Therapeutics NV Market data — financials · 2026-05-29
- Vivoryon Therapeutics NV Market data — analyst estimates · 2026-05-29